Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

BACKGROUND * Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary VEGF and MMP level at the one month follow-up time point compared to the last on-treatment time point collection may be predictive of tumor recurrence at one year. * Note that this preliminary study included patients with all histologies. * In an ongoing effort to validate our results with a larger more homogeneous patient cohort we propose to prospectively study patients undergoing radiotherapy for GBM. OBJECTIVES -We will determine whether VEGF and MMP level measurements aid in predicting tumor recurrence at 1 year. ELIGIBILITY -Patients seen in the radiation oncology clinic will be asked to provide samples of blood and urine before, during and after their radiation treatment. DESIGN * This protocol-provides a means of acquiring blood and urine samples from patients receiving radiation therapy for Glioblastoma multiforme (GBM). * Patients will be analyzed according to their Radiation Therapy Oncology Group (RTOG) recursive partitioning prognostic subgroups, which includes patient age, KPS, extent of resection and neurological function.